Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
Personalized mRNA Tumor Vaccine
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx"
Atrium Therapeutics
Cancer
1 trial -
Postoperative radiotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Oral Tongue Squamous Cell Carcinoma
1 trial -
Prediction Model Arm
The First People's Hospital of Lianyungang
Lung Cancer Screening
1 trial -
Preoperative three-dimensional reconstruction
Universal Integrated
Kidney Neoplasms / Surgery
1 trial -
Propofol
Hospital Authority, Hong Kong
Renal Cell Carcinoma
1 trial -
Prostate biopsy
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
R-CDOP
The First People's Hospital of Lianyungang
Diffuse Large B Cell Lymphoma
1 trial -
RNAseq
Takeda
Non-small Cell Lung Cancer
1 trial -
Radiation
Adaptive Biotechnologies Corp
Rectal Cancer
1 trial -
Radiation therapy
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Radiotherapy combined with TKI and Anti-PD-1 Antibody
Jian Li
Stage IIIA Hepatocellular Carcinoma
1 trial -
Raman spectrum
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer
1 trial -
Reduction CTVp1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Regorafenib and Sintilimab in combination with electroacupuncture
The First People's Hospital of Lianyungang
Colorectal Cancer Metastatic
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral T-Cell Lymphoma, Not Otherwise Specified
1 trial -
Ropivacaine Hydrochloride 10 MG/ML [Naropin]
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colorectal Cancer
1 trial -
SPECT/CT imaging with 99mTc-P137 nuclide probe
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Sheng-Yu-Tang
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Leukemia
1 trial -
Short course palliative radiation.
Hospital Authority, Hong Kong
Cervical Cancer
1 trial -
Surgery combined with Target-reduction intensity-modulated radiotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Surgery-radiotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma
1 trial -
TRT
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Thalidomide
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma
1 trial -
Tislelizumab combined with Lenvatinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Initially Unresectable Hepatocellular Carcinoma
1 trial -
Tumor Specific Antigen-loaded Dendritic Cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Tumor Gastric
1 trial -
Tumour Biopsy and Venous Blood Tests
United Therapeutics Europe Ltd
Soft Tissue Sarcoma
1 trial -
UE
The First People's Hospital of Lianyungang
Lung Cancer
1 trial -
UW 22-704
The University of Hong Kong
Recurrent Ovarian Carcinoma
1 trial -
Venclexta 100 MG Oral Tablet
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Whole Body Non-Contrast MRI
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
XMYY-2024KY024
The First People's Hospital of Lianyungang
Tumor
1 trial -
XMYY-2025KY231
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
XMYY-2025KY280
The First People's Hospital of Lianyungang
DLL3-expressing Tumors
1 trial -
Yishen Qutong Granules
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Esophageal Squamous Cell Carcinoma (ESCC)
1 trial -
[68Ga]P3
The First People's Hospital of Lianyungang
Neoplasms
1 trial -
anti-thymocyte globulin
United Therapeutics Europe Ltd
Leukemia
1 trial -
blood sampling
Marker Therapeutics
Screening for Colon Cancer
1 trial -
blood sampling
Marker Therapeutics
Colorectal Cancer Screening
1 trial -
bpMRI
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
brachytherapy
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
chemotherapy plus TCM 1&ICIs plusTCM2
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer
1 trial -
chlorhexidine acetate gargle
Peking University Third Hospital
Esophageal Cancer
1 trial -
circulate free methylated EBV DNA
The First People's Hospital of Lianyungang
Extranodal Natural Killer/T-cell Lymphoma
1 trial -
circulating tumor cells test
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Thyroid Nodule
1 trial -
conventional radiotherapy 74 Gy delivered in 37 fractions
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
erlotinib (Tarceva) and bexarotene (Targretin)
LIGAND PHARMACEUTICALS INC
Carcinoma, Non-small-cell Lung
1 trial -
fludeoxyglucose F 18
United Therapeutics Europe Ltd
Lung Cancer
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.